456 related articles for article (PubMed ID: 29080340)
1. Bile Acids in Cholestasis and its Treatment.
Arab JP; Cabrera D; Arrese M
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s53-s57. PubMed ID: 29080340
[TBL] [Abstract][Full Text] [Related]
2. Bile Acids in Cholestasis and its Treatment.
Pablo Arab J; Cabrera D; Arrese M
Ann Hepatol; 2017 Nov; 16 Suppl 1():S53-S57. PubMed ID: 31196636
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of bile acid mediated inflammation in the liver.
Li M; Cai SY; Boyer JL
Mol Aspects Med; 2017 Aug; 56():45-53. PubMed ID: 28606651
[TBL] [Abstract][Full Text] [Related]
5. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Cabrera D; Arab JP; Arrese M
Handb Exp Pharmacol; 2019; 256():237-264. PubMed ID: 31236688
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis.
Ghallab A; González D; Strängberg E; Hofmann U; Myllys M; Hassan R; Hobloss Z; Brackhagen L; Begher-Tibbe B; Duda JC; Drenda C; Kappenberg F; Reinders J; Friebel A; Vucur M; Turajski M; Seddek AL; Abbas T; Abdelmageed N; Morad SAF; Morad W; Hamdy A; Albrecht W; Kittana N; Assali M; Vartak N; van Thriel C; Sous A; Nell P; Villar-Fernandez M; Cadenas C; Genc E; Marchan R; Luedde T; Åkerblad P; Mattsson J; Marschall HU; Hoehme S; Stirnimann G; Schwab M; Boor P; Amann K; Schmitz J; Bräsen JH; Rahnenführer J; Edlund K; Karpen SJ; Simbrunner B; Reiberger T; Mandorfer M; Trauner M; Dawson PA; Lindström E; Hengstler JG
J Hepatol; 2024 Feb; 80(2):268-281. PubMed ID: 37939855
[TBL] [Abstract][Full Text] [Related]
7. Inflammation Drives MicroRNAs to Limit Hepatocyte Bile Acid Transport in Murine Biliary Atresia.
Azeltine MW; Chavez EJ; Nemec KM; Bednarek JM; Asokan R; Balasubramaniyan N; Zgheib C; Mack CL; Roach JP
J Surg Res; 2020 Dec; 256():663-672. PubMed ID: 32818799
[TBL] [Abstract][Full Text] [Related]
8. Bile acids in regulation of inflammation and immunity: friend or foe?
Zhu C; Fuchs CD; Halilbasic E; Trauner M
Clin Exp Rheumatol; 2016; 34(4 Suppl 98):25-31. PubMed ID: 27586800
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects.
Roma MG; Crocenzi FA; Sánchez Pozzi EA
Clin Sci (Lond); 2008 May; 114(9):567-88. PubMed ID: 18377365
[TBL] [Abstract][Full Text] [Related]
10. Bile acid transporters: structure, function, regulation and pathophysiological implications.
Alrefai WA; Gill RK
Pharm Res; 2007 Oct; 24(10):1803-23. PubMed ID: 17404808
[TBL] [Abstract][Full Text] [Related]
11. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
12. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans.
Caballero-Camino FJ; Rodrigues PM; Wångsell F; Agirre-Lizaso A; Olaizola P; Izquierdo-Sanchez L; Perugorria MJ; Bujanda L; Angelin B; Straniero S; Wallebäck A; Starke I; Gillberg PG; Strängberg E; Bonn B; Mattsson JP; Madsen MR; Hansen HH; Lindström E; Åkerblad P; Banales JM
Hepatology; 2023 Sep; 78(3):709-726. PubMed ID: 36999529
[TBL] [Abstract][Full Text] [Related]
13. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.
Yang K; Köck K; Sedykh A; Tropsha A; Brouwer KL
J Pharm Sci; 2013 Sep; 102(9):3037-57. PubMed ID: 23653385
[TBL] [Abstract][Full Text] [Related]
14. Alpha-naphthylisothiocyanate impairs bile acid homeostasis through AMPK-FXR pathways in rat primary hepatocytes.
Li X; Liu R; Yu L; Yuan Z; Sun R; Yang H; Zhang L; Jiang Z
Toxicology; 2016 Aug; 370():106-115. PubMed ID: 27702592
[TBL] [Abstract][Full Text] [Related]
15. Geniposide attenuates ANIT-induced cholestasis through regulation of transporters and enzymes involved in bile acids homeostasis in rats.
Wang L; Wu G; Wu F; Jiang N; Lin Y
J Ethnopharmacol; 2017 Jan; 196():178-185. PubMed ID: 27988401
[TBL] [Abstract][Full Text] [Related]
16. The ascending pathophysiology of cholestatic liver disease.
Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
[TBL] [Abstract][Full Text] [Related]
17. Bile acid interactions with cholangiocytes.
Xia X; Francis H; Glaser S; Alpini G; LeSage G
World J Gastroenterol; 2006 Jun; 12(22):3553-63. PubMed ID: 16773712
[TBL] [Abstract][Full Text] [Related]
18. Bile salts and cholestasis.
Maillette de Buy Wenniger L; Beuers U
Dig Liver Dis; 2010 Jun; 42(6):409-18. PubMed ID: 20434968
[TBL] [Abstract][Full Text] [Related]
19. IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis.
O'Brien KM; Allen KM; Rockwell CE; Towery K; Luyendyk JP; Copple BL
Am J Pathol; 2013 Nov; 183(5):1498-1507. PubMed ID: 24012680
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.
Petrescu AD; DeMorrow S
Cells; 2021 Jul; 10(8):. PubMed ID: 34440614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
